Scitegrity supported drug receives FDA approval
Scitegrity supported drug receives FDA approval
The drug to treat Lambert-Eaton myasthenic syndrome (LEMS) in adults approved. Drug Abuse Potential assessments supported by Scitegrity
Catalyst Pharma have announced the FDA have approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Scitegrity supported Catalyst Pharma’s NDA submission by providing Drug Abuse Potential expertise and assessments for use in the NDA submission.
LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
Trusted by our Clients
![cayman](https://blog.scitegrity.com/hubfs/cayman.png)
![LGC_standards-1](https://blog.scitegrity.com/hubfs/LGC_standards-1.jpg)
![Roche](https://blog.scitegrity.com/hubfs/Roche.png)
![gsk](https://blog.scitegrity.com/hubfs/gsk.png)
![Boehringer](https://blog.scitegrity.com/hubfs/Boehringer.png)
![Merck_logo](https://blog.scitegrity.com/hubfs/Merck_logo.jpg)
![HomeOffice logo](https://blog.scitegrity.com/hubfs/HomeOffice%20logo.jpg)
![sygnature_logo](https://blog.scitegrity.com/hubfs/sygnature_logo.png)
![UCB](https://blog.scitegrity.com/hubfs/UCB.png)
![AstraZeneca](https://blog.scitegrity.com/hubfs/AstraZeneca.jpg)
![Biosynth_logo_new](https://blog.scitegrity.com/hubfs/Biosynth_logo_new.png)